Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
Department of Plastic Surgery, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
J Reconstr Microsurg. 2022 Jan;38(1):75-83. doi: 10.1055/s-0041-1731302. Epub 2021 Jul 6.
The role of vasopressors has long been a subject of debate in microsurgery. Conventional wisdom dictates the avoidance of vasopressor use, due to concerns such as peripheral vasoconstriction, inducing vasospasm of the anastomoses, and leading to failure in perfusion. It has since become common practice in some centers to avoid intraoperative vasopressor use during free tissue transfer surgery. Recent studies have suggested that this traditional view may not be supported by clinical evidence. However, none of these studies have separated vasopressor use by method of administration.
We conducted a retrospective review of our experience of vasopressor use in free flap surgery at a single high-volume center. The outcome measures were flap failure, flap-related complications and overall postoperative complications (reported using the Clavien-Dindo classification). Groups were compared using Chi-square or Fisher's Exact test where appropriate.
A total of 777 cases in 717 patients were identified. 59.1% of these had vasopressors administered intraoperatively. The overall failure rate was 2.2%, with 9.8% experienced flap-related complications. There was no difference in flap loss when vasopressors were administered, but an increased rate of microvascular thrombosis was noted ( = 0.003). Continuous administration of vasopressors was associated with reduced venous congestion, whereas intermittent boluses increased risk of microvascular thrombosis.
Our study confirms previous findings that intraoperative vasopressor use in free flap surgery is not associated with increased failure rate. Administering vasopressors continuously may be safer than via repeated boluses.
血管加压剂在显微外科中的作用一直存在争议。传统观点认为应避免使用血管加压剂,因为担心其会引起外周血管收缩,诱发吻合口血管痉挛,并导致灌注失败。因此,在一些中心,术中避免在游离组织转移手术中使用血管加压剂已成为常规做法。最近的研究表明,这种传统观点可能没有临床证据支持。然而,这些研究都没有通过给药方式来区分血管加压剂的使用。
我们对单一高容量中心游离皮瓣手术中血管加压剂使用的经验进行了回顾性研究。主要观察指标为皮瓣失败、皮瓣相关并发症和总体术后并发症(采用 Clavien-Dindo 分类进行报告)。使用卡方检验或 Fisher 精确检验比较组间差异。
共确定了 717 例患者中的 777 例,其中 59.1%的患者术中给予了血管加压剂。总的失败率为 2.2%,有 9.8%的患者出现皮瓣相关并发症。使用血管加压剂与皮瓣丢失率无差异,但观察到微血管血栓形成的发生率增加(=0.003)。连续给予血管加压剂与减少静脉淤血有关,而间断给予血管加压剂则增加了微血管血栓形成的风险。
我们的研究证实了先前的发现,即在游离皮瓣手术中术中使用血管加压剂不会增加失败率。连续给予血管加压剂可能比重复给予血管加压剂更安全。